Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRINITY trial of mycophenolate mofetil plus prednisolone in chronic virus-negative inflammatory cardiomyopathy
2021-005875-38Phase 2Active
- Sponsor
- LMU Klinikum
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in inflammatory cardiomyopathy, dilated cardiomyopathy (DCM) and Cardiomyopathies comparing Mycophenolate mofetil + prednisolone with Placebo (2 arms). Primary endpoint: Co-primary endpoints. Started May 2022; status: active.
02
Drugs
mycophenolate mofetilprednisolone
03
Conditions
inflammatory cardiomyopathydilated cardiomyopathy (DCM)Cardiomyopathies
Beyond the preview
Go deeper on 2021-005875-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005875-38.